{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T09:11:33Z","timestamp":1759569093802,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":548,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007338","name":"Foundation for Barnes-Jewish Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014571","name":"Siteman Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.exphem.2024.104178","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:51:51Z","timestamp":1707439911000},"page":"104178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms"],"prefix":"10.1016","volume":"132","author":[{"given":"Taylor B.","family":"Collins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo B.A.","family":"Laranjeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary C.","family":"Fulbright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.C.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-4414","authenticated-orcid":false,"given":"Christopher M.","family":"Sturgeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.Z.","family":"Batista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-5400","authenticated-orcid":false,"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2024.104178_bib0001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.hoc.2020.12.002","article-title":"Genetics of myeloproliferative neoplasms","volume":"35","author":"Szybinski","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.exphem.2024.104178_bib0002","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2024.104178_bib0003","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2024.104178_bib0004","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2024.104178_bib0005","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1172\/JCI70739","article-title":"Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations","volume":"123","author":"Inoue","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2024.104178_bib0006","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1038\/ncomms8307","article-title":"Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex","volume":"6","author":"Balasubramani","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2024.104178_bib0007","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41375-018-0198-6","article-title":"Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification","volume":"33","author":"Uni","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2024.104178_bib0008","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13045-017-0508-x","article-title":"The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model","volume":"10","author":"Hsu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2024.104178_bib0009","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/s41467-021-22053-y","article-title":"Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt\/mTOR pathway","volume":"12","author":"Fujino","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2024.104178_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ymeth.2015.10.001","article-title":"Directed differentiation of definitive hemogenic endothelium and hematopoietic progenitors from human pluripotent stem cells","volume":"101","author":"Ditadi","year":"2016","journal-title":"Methods"},{"key":"10.1016\/j.exphem.2024.104178_bib0011","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/ajh.26935","article-title":"Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms","volume":"98","author":"Kong","year":"2023","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.exphem.2024.104178_bib0012","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-182320","article-title":"RSK1 is an exploitable dependency in myeloid malignancies","volume":"142","author":"Kong","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104178_bib0013","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1158\/2159-8290.CD-20-1652","article-title":"A humanized animal model predicts clonal evolution and therapeutic vulnerabilities in myeloproliferative neoplasms","volume":"11","author":"Celik","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2024.104178_bib0014","first-page":"108","article-title":"DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression","volume":"4","author":"Kong","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.exphem.2024.104178_bib0015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/bloodadvances.2020002804","article-title":"Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NF\u03baB pathway inhibition","volume":"6","author":"Kong","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2024.104178_bib0016","doi-asserted-by":"crossref","first-page":"28789","DOI":"10.1038\/srep28789","article-title":"ASXL1 plays an important role in erythropoiesis","volume":"6","author":"Shi","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2024.104178_bib0017","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1084\/jem.20131141","article-title":"Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo","volume":"210","author":"Abdel-Wahab","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2024.104178_bib0018","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/blood-2013-05-500272","article-title":"Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104178_bib0019","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2021006350","article-title":"ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2024.104178_bib0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3324\/haematol.2017.174516","article-title":"Protein arginine methyltransferase 6 controls erythroid gene expression and differentiation of human CD34+ progenitor cells","volume":"103","author":"Herkt","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2024.104178_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2022.12.003","article-title":"Decoding m6A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance","volume":"30","author":"Cheng","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2024.104178_bib0022","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41389-021-00332-z","article-title":"PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1","volume":"10","author":"Schneider","year":"2021","journal-title":"Oncogenesis"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X24000377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X24000377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:39:11Z","timestamp":1759567151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X24000377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":22,"alternative-id":["S0301472X24000377"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2024.104178","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2024.104178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104178"}}